← All trials
NCT06524583
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2024
- Primary completion
- Dec 31, 2029
- Completion date
- Dec 31, 2030
- First posted
- Jul 29, 2024
- Last posted
- Jul 29, 2024
- Enrollment
- 198
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- UNICANCERLead sponsor
- National Research Agency, FranceCollaborator
- PharmaMarCollaborator
- Ligue contre le cancer, FranceCollaborator
- Institut BergoniéCollaborator
- University of ToulouseCollaborator
- Aix-University of MarseilleCollaborator
- Aix-University of MarseilleOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.